Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06356701
Status:
RECRUITING
Last Update Posted:
2024-04-10
First Post:
2024-03-20
Brief Title:
Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC
Sponsor:
The First Affiliated Hospital of Dalian Medical University
Organization:
The First Affiliated Hospital of Dalian Medical University
Study Overview
Official Title:
A Single-center Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Single-center Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Tumor Nutritional Therapy Combined With Immune Checkpoint Inhibitors and Chemotherapy in the First-line Treatment of Stage IV NSCLC Without Driver Gene Mutations
Detailed Description:
Main purpose Cancer nutritional treatment regimen Spirulina Bifidobacterium Capsules Fish Oil Grape Seed Blueberry Soft Capsules Ganoderma Spore Oil Soft Capsules combined with immune checkpoint inhibitors and chemotherapy in the first-line treatment of stage IV non-small cell lung cancer without driver gene mutations efficacy inSecondary purpose Cancer nutritional treatment regimen Spirulina Bifidobacterium Capsules Fish Oil Grape Seed Blueberry Soft Capsules Ganoderma Spore Oil Soft Capsules combined with immune checkpoint inhibitors and chemotherapy in the first line of stage IV non-small cell lung cancer without driver gene mutations Safety in treatmentExploratory purpose Tumor nutritional treatment regimen Spirulina Bifidobacterium Capsules Fish Oil Grape Seed Blueberry Soft Capsules Ganoderma Spore Oil Soft Capsules combined with immune checkpoint inhibitors and chemotherapy in the first line of stage IV non-small cell lung cancer without driver gene mutations The relationship between the number of T cell subpopulations and changes in inflammatory factors during treatment and the therapeutic effect and whether the T cell subpopulation analysis method can effectively monitor and evaluate the status of the tumor immune microenvironment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None